Health Care

Insider buys reveal TG Therapeutics’ confidence: CFO’s long‑term stake and CEO’s open‑market purchase hint at undervaluation and future growth amid market volatility.

Insider sell‑to‑cover at Avidity Biosciences shows execs stay long‑term on the sidelines while the company pursues antibody‑oligonucleotide breakthroughs—read why this matters for investors.

BioVie’s insider option buying signals executive confidence in its Parkinson’s and liver‑cirrhosis pipeline, hinting at potential upside if FDA milestones are met.

Neumora Therapeutics’ insider buying surge shows board confidence in a promising Parkinson’s pipeline, strong Phase II safety, and a clear path to FDA approval, making it a hot watch for investors in neuro‑therapeutics.

Merck’s final insider deal completes its takeover of Cidara Therapeutics—closing a cashless, $221.50‑per‑share merger that adds a promising anti‑infective pipeline and boosts investor confidence.

Explore how Stryker’s steady insider holdings, modest option vesting and routine sales reveal a long‑term, value‑driven strategy amid strong earnings and a $140 billion market cap.

Ionis insider buying signals confidence in its RNA platform and highlights the shift to tech‑enabled, value‑based healthcare delivery and reimbursement models.

Milestone Pharmaceuticals’ 10b5‑1 insider trades reveal disciplined liquidity management—boosting R&D funding, market access, and partnership potential for its metabolic‑disorder pipeline.

Acumen Pharmaceuticals’ insider sales are a routine Rule 10b5‑1 tax plan, not a warning; the company’s tau‑inhibitor breakthrough therapy and beta‑amyloid trials still hold upside while short‑term volatility and social‑media buzz keep investors caut…

Discover how Revolution Medicines COO Margaret Horn’s 10(b)(5)(1) trades reveal insider confidence, strategic liquidity, and pipeline optimism in the high‑volatility oncology sector.